Navigation Links
Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease
Date:6/22/2009

t costs on a 50/50 basis, and in return Shire received rights to commercialize these products outside of the U.S. while Amicus retains all rights to commercialize these products in the U.S. In addition, Amicus leads development operations through the end of Phase 2 clinical trials. The companies then share responsibility for Phase 3 clinical trial development leveraging Shire's significant ex-U.S. regulatory and clinical experience as well as its commercial infrastructure.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs.

Amicus has a strategic collaboration with Shire Human Genetic Therapies, Inc., a wholly-owned subsidiary of Shire Limited, to develop and commercialize Amicus' three lead pharmacological chaperone compounds for lysosomal storage disorders. Under the agreement, Shire received commercial rights outside of the United States. Amicus retains all U.S. rights.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should" and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances,
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
11. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 According to a ... Devices Market (Endoscopes, Endoscopic Operative Devices, and Visualization Systems) ... Forecast, 2013-2019" the global endoscopy devices market was valued ... to grow at a CAGR of 6.8% from 2013 ... 36.9 billion in 2019. Browse the full ...
(Date:7/11/2014)... 2014 Neurelis, Inc. ("Neurelis") today announced an ... option held by Biotie to purchase Neurelis, clearing the ... (intranasal diazepam) for pediatric and adult epilepsy patients who ... year, Biotie has advanced the development program for NRL-1 ... clinical work required for NDA submission to the FDA.  ...
(Date:7/10/2014)... 2014  Breg, Inc., a premier provider of ... FreeRunner™ knee brace with new innovations to help ... return to active lifestyles.  FreeRunner,s patent-pending design acts ... support when patients need it most, and the ... Patellofemoral issues are the most common cause ...
Breaking Medicine Technology:Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2
(Date:7/11/2014)... -- People with the lowest incomes may have a higher ... a new study suggests. People with PAD have narrowing ... often the legs. The condition causes leg pain and is ... body. People with PAD have a higher risk for heart ... people with PAD who took part in the U.S. National ...
(Date:7/11/2014)... The report, “Specialty Synthetic Fibers & Glass ... 2018,” defines and segments the specialty synthetic fibers ... forecast of the volumes and values of types ... aramids, UHMW Polyethylene, carbon fiber, partially oxidized polyacrylonitrile ... PBO fiber, and liquid crystal polymer fiber and ...
(Date:7/11/2014)... News) -- In people with sex addiction, pornography affects ... seen in drug addicts as they consume drugs, a ... brain activity between patients who have compulsive sexual behavior ... addicts," study author Dr. Valerie Voon, of the University ... release. Voon,s research involved 19 men with sex ...
(Date:7/11/2014)... Alliance for Cancer Gene Therapy, Inc. ... to cell and gene therapies for cancer – ... organization as Senior Development Officer. , Corday is ... gifts and addressing influential donors. Prior to joining ... NewYork Presbyterian Hospital/Columbia University Medical Center, where he ...
(Date:7/11/2014)... 2014 As reported by the ... 7/11/14), a significant number of severe adverse events such ... and even death from the highly-promoted and costly immune-system ... Times report , a regulatory filing revealed that ... patients was almost 14% of prescriptions, up from 9.1% ...
Breaking Medicine News(10 mins):Health News:Poor More Prone to Leg Circulation Trouble 2Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 2Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 3Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 4Health News:Brains of Sex Addicts May Be Wired Like Those of Drug Addicts, Study Finds 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 3Health News:Acthar’s Deadly Adverse Events Revealed 2Health News:Acthar’s Deadly Adverse Events Revealed 3
... many human beings. A new Mayo Clinic study reveals the ... definition of contact dermatitis is that it is a skin ... direct contact with an allergen. ,The ten allergens ... ,? Nickel (nickel sulfate hexahydrate ,? Gold (gold sodium ...
... data on men's health over the last two decades. The ... a semi annual survey.// Judging by the response, the Harvard ... on how men can maintain a satisfying sex life, as ... most prevalent illness in elderly men followed by chronic illnesses ...
... Mumbai were crippled as the striking doctors were determined to ... All the government hospitals in Mumbai suffered due to absence ... 15 government-managed hospitals in this bustling city of over 15 ... demanding better security while on the job after relatives of ...
... Cyriac Joseph has expressed the need for quality medical ... not leave any stone unturned to weed out black ... this is a matter of grave concern to the ... The educationists, professionals, governments and all the stakeholders in ...
... from Duke university Medical Center have established that ... influenced by a complex interplay between genetic and ... crucial role in determining the psychological and biological ... results of four such studies that examined the ...
... that the much dreaded bird flu virus may be carried across ... the potential of posing a serious health hazard, specifically in the ... bird flu viral strain. ,The exact mechanism of how ... if bird flu virus is found in birds in U.K, it ...
Cached Medicine News:Health News:Health Services Came To A Halt As Mumbai Doctors Strike Continues 2Health News:Genes And Environmental Factors Determine Stress Response 2
Curved shafts with 2.0 mm wide serrated tips and 0.4 mm pin in upper jaw. Serrated cross action handle with dull finish....
Angled insertion forcep used for the Hydroview lens. Manufactured in titanium....
Biconvex jaw design. 40 degree angled shafts. Tip to angle length: 7.5 mm. Locking handle. Manufacturing in titanium....
Titanium. Designed to easily fold the hydroview lens. Will also fold many styles of soft intraocular lenses. Unique cross-action design facilitates folding of the lens....
Medicine Products: